Latest Centocor Stories

TITUSVILLE, N.J., Aug. 30, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced a settlement and consent decree today with 36 states and the District of Columbia regarding previously disclosed allegations related to promotional and marketing practices for its atypical antipsychotic prescription medication RISPERDAL®. The company will pay approximately $181 million, an amount which has been previously accrued, as part of a consent decree to...

SKILLMAN, N.J., Aug. 15, 2012 /PRNewswire-FirstCall/ -- The Johnson & Johnson Family of Consumer Companies today announced the launch of www.SafetyandCareCommitment.com an initiative to help consumers better understand all the measures we take to make our beauty and baby care products as safe as can be. "There's a public discussion underway about the ingredients in beauty care products, and we think it's important to be part of that," said Susan Nettesheim, Vice President of...

The Rottenstein Law Group, which represents clients with claims stemming from injuries allegedly caused by vaginal mesh products including those that were manufactured by the Johnson & Johnson subsidiary Ethicon, has learned that Johnson & Johnson is making policy changes that will enable its board of directors and C-level executives to better oversee the company's subsidiaries. New York, NY (PRWEB) July 17, 2012 Johnson & Johnson has agreed to create a board-level group...

~ Thousands walked to help find a cure for one of Canada's leading causes of disability ~ TORONTO, June 11, 2012 /CNW/ - The 3(rd) annual Walk to Fight Arthritis presented by the makers of TYLENOL®, held on Sunday, June 10(th) in 21 communities across Canada, was hailed as a resounding success by all who attended.  In total, almost $1.6 million was raised, bringing the total raised over the course of 3 years of the Walk to almost $3.9 million.  In total, 8,000 participants took...

NEW BRUNSWICK, N.J., June 8, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced it expects to incur a special charge in the second quarter of 2012 of approximately $600 million to increase its accrual for the potential settlement of previously disclosed civil litigation matters related to RISPERDAL® (risperidone), INVEGA® (paliperidone), NATRECOR® (nesiritide) and Omnicare, Inc. About Johnson & JohnsonCaring for the world, one person at a time,...

VERONA, Italy, June 6, 2012 /PRNewswire/ -- New efficacy and safety data from the Phase 3 PHOENIX 1 study, one of two pivotal registration trials, showed that maintenance treatment with STELARA® (ustekinumab) for up to five years resulted in consistent, significant clinical response in adults with moderate to severe plaque psoriasis. Among responders receiving STELARA 45 mg or 90 mg and randomized to continue maintenance therapy through five years, 79 and 81 percent of patients,...

NEW BRUNSWICK, N.J., May 2, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference on Wednesday, May 9, at The InterContinental Boston in Boston, MA. Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session scheduled at 10:40 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the...

NEW BRUNSWICK, N.J., April 26, 2012 /PRNewswire/ -- After 10 years presiding over Johnson & Johnson (NYSE: JNJ) during a period of extraordinary change in the health care industry, Chairman and Chief Executive Officer Bill Weldon officially transferred responsibilities for running the company to incoming CEO Alex Gorsky at the Annual Meeting of Shareholders held today. Weldon remains Chairman of the Board and Gorsky, who was elected to the Board of Directors today, begins...

NEW BRUNSWICK, N.J., April 19, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 26, 2012, from the Hyatt Regency Hotel in New Brunswick, N.J. Investors and other interested parties may access the live webcast of the meeting by visiting the Company's website at www.jnj.com and clicking on the webcast icon. A replay of presentations from the meeting will be made available a few...

NEW BRUNSWICK, N.J., April 9, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) said today that Sheri S. McCoy, Vice Chairman of the Executive Committee, has resigned from the Company effective April 18 to join another publicly traded company as CEO. Ms. McCoy joined Johnson & Johnson in 1982 and was appointed to her current responsibilities in January, 2011. William C. Weldon, Chairman and CEO, said, "Sheri has made important contributions across Johnson & Johnson...